NR4A1 and breast carcinoma: Human epidermal growth factor receptor 2 (HER2)-positive breast cancer accounts for 20%-30% of all breast cancers, with HER2-positive/hormone receptor (HR)-positive cases accounting for approximately 50% of the cases and HR-negative cases accounting for approximately 30% (4).